Substance P regulates memory Th17 cell generation and maintenance in chronic dry eye disease
Journal of Leukocyte Biology · 27.11.2024 · 116 (6) · 1446-1453
DOI: 10.1093/jleuko/qiae142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 25.06.2024. Verfasst von Shudan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, United States. Hauptthemen laut MEDLINE: Th17 Cells, Dry Eye Syndromes, Substance P, Immunologic Memory. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, Massachusetts Eye and Ear, NIH HHS.
Abstract (Originalsprache)
Substance P is a neuropeptide expressed by nerves and an array of cells that serves as a critical mediator of neuroinflammation. Our recent work has demonstrated that blocking the preferred receptor for substance P, neurokinin 1 receptor, effectively suppresses the induction of acute dry eye disease by preserving regulatory T-cell function, while inhibiting antigen-presenting cell maturation and subsequent generation of effector Th17 cells. Clinically, dry eye disease is a chronic disorder characterized by sustained ocular surface inflammation, which is mediated by long-lived memory Th17 cells demonstrated in our well-established chronic dry eye disease model. The present study aimed to further understand the function of substance P in the chronic phase of dry eye disease and its role in regulating the underlying pathogenic memory Th17. In vitro culture of effector T cells isolated from acute dry eye disease with substance P led to an enhanced conversion of effector Th17 to memory Th17, while culturing memory T cells isolated from chronic dry eye disease with substance P effectively preserved the memory Th17 cells. In contrast, the addition of a neurokinin 1 receptor antagonist in the cultures abolished the substance P–mediated effects. Furthermore, in vivo treatment with the neurokinin 1 receptor antagonist during the resolution phase of acute dry eye disease significantly suppressed memory Th17 generation, and treatment in the chronic phase of dry eye disease disrupted the maintenance of memory Th17. Taken together, our results demonstrate that increased expression of substance P promotes memory Th17 generation and maintenance in chronic dry eye disease, and thus blockade of substance P represents a novel promising memory Th17–targeting strategy in treating chronic ocular surface inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, United States.
- Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical University, 143 Yiman Street, Harbin, Heilongjiang Province, 150001, P.R. China.
ORCID-Profile: Yihe Chen
Förderung
- NEI NIH HHS
- Massachusetts Eye and Ear
- NIH HHS
- National Institutes of Health
Zitieren
APA
Wang, S., Naderi, A., Kahale, F., Ortiz, G., Forouzanfar, K., Chen, Y., & Dana, R. (2024). Substance P regulates memory Th17 cell generation and maintenance in chronic dry eye disease. Journal of Leukocyte Biology, 116(6), 1446-1453. https://doi.org/10.1093/jleuko/qiae142
Vancouver
Wang S, Naderi A, Kahale F, Ortiz G, Forouzanfar K, Chen Y, et al. Substance P regulates memory Th17 cell generation and maintenance in chronic dry eye disease. Journal of Leukocyte Biology. 2024;116(6):1446-1453. doi:10.1093/jleuko/qiae142
BibTeX
@article{Wang2024,
author = {Wang, Shudan and Naderi, Amirreza and Kahale, Francesca and Ortiz, Gustavo and Forouzanfar, Katayoon and Chen, Yihe and Dana, Reza},
title = {Substance P regulates memory Th17 cell generation and maintenance in chronic dry eye disease},
journal = {Journal of Leukocyte Biology},
year = {2024},
volume = {116},
number = {6},
pages = {1446--1453},
doi = {10.1093/jleuko/qiae142}
}
EUVIMED